Cerus (CERS)
Supplies illuminators and disposable kits that inactivate pathogens in donated platelets, plasma and fibrinogen concentrate.
Something off on this page? Send us feedback.
Sells illuminator devices and single-use kits that treat donated platelets and plasma with a light-activated compound to inactivate pathogens before transfusion, plus a fibrinogen concentrate made from the same plasma system. Revenue is recurring kit sales at blood centers running the equipment, supplemented by government funding for red-blood-cell and whole-blood treatments in development.
Built around a single chemistry — a light-activated compound that binds pathogen DNA and RNA to block replication — the INTERCEPT Blood System treats donated platelets and plasma for use in transfusions. The chemistry traces to 1980s research responding to HIV-contaminated blood supplies.
Illuminator devices sold to blood centers pair with single-use disposable kits, a recurring-revenue model built on equipment already installed. Plasma treated through the system is also processed into a fibrinogen concentrate for bleeding control, currently the fastest-growing product line.
European blood centers adopted the platelets and plasma systems years before United States regulatory clearance arrived; both regions now use them. Red-blood-cell and whole-blood versions are in later-stage development, work substantially funded through government contracts.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| May 1, 2026 | BTIG | Upgrade | Target: — | Target: $4 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $56.3M · Total debt $76.8M · Total assets $205.2M · Shareholders' equity $70.0M
- Revenue
- $57.4M
- Operating income
- −$1.9M
- Net income
- −$2.9M
No dividends on record.
| Institutions | ≈ 75.16% | 151.47M shares | |
|---|---|---|---|
| 191 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 2.88% | 5.80M shares | |
| 11 holders · as of Aug 17, 2026 | |||
| Other | ≈ 21.96% | 44.25M shares | |
| remainder | |||
201.52M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
BlackRock, Inc.Institution | 11.02% | 22.22M | as of Jun 30, 2026 |
Ark Investment Management LLCInstitution | 8.90% | 17.93M | as of Jun 30, 2026 |
Soleus Capital Master Fund, L.P.Institution | 4.88% | 9.83M | filed Mar 24, 2026 |
Vanguard Capital Management LLCInstitution | 4.25% | 8.56M | as of Jun 30, 2026 |
Baker Bros. Advisors LPInstitution | 3.17% | 6.40M | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Aug 17, 2026 | Chrystal Jensen | officer: Chief Legal Officer | −30,000 | $2.98 |
| Jul 16, 2026 | Vivek K. Jayaraman | officer: Chief Executive Officer | −16,666 | $3.16 |
| Jun 30, 2026 | William Mariner Greenman | director, officer: President and CEO | −101,919 | $2.94 |
| Jun 30, 2026 | Chrystal Jensen | officer: Chief Legal Officer | −24,329 | $2.94 |
| Jun 30, 2026 | Vivek K. Jayaraman | officer: Chief Operating Officer | −42,359 | $2.94 |
- Abbott
Diagnostics giant screening most of world's blood supply for infections
- Grifols (ADR)
Diagnostics arm rivals pathogen reduction via NAT donor screening
- Haemonetics
Diversified blood-collection and transfusion-management medtech; not a PRT rival
CompareAfter hours
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Cerus | $2.67 | +0.19% | $515.9M | — | — | 2.3 | +20.7% |
| Abbott | $103.69 | −0.03% | $178.18B | 33.1 | 17.9 | 3.8 | +13.0% |
| Grifols (ADR) | $7.44 | 0.00% | $6.23B | 9.6 | — | 0.7 | −1.8% |
| Haemonetics | $108.52 | −0.03% | $4.94B | 53.3 | 19.7 | 3.7 | +5.6% |
| Median | 33.1 | 18.8 | 3.7 | +5.6% |